Background: Electroconvulsive Therapy (ECT) remains a highly effective intervention for severe psychiatric disorders yet concerns about cognitive and emotional side effects persist. Integrated psychoeducational psychiatric nursing intervention plays a pivotal role in mitigating these challenges, promoting patient safety, and enhancing therapeutic outcomes. So, this study aimed to evaluate the effectiveness of integrated psychoeducational psychiatric nursing intervention on health-related quality of life, emotional well-being and anxiety in patients receiving modified electroconvulsive therapy. Subjects and method: A quasi-experimental research design was utilized from January 2026 to April 2026. Setting: The study was conducted at two psychiatric inpatient hospitals in shebin elkom, Menoufia Governorate, Egypt. Subjects: A purposive sample of sixty patients was selected from the previously mentioned setting. Tools of data collection: Four valid tools were used in data collection: tool 1: A structured interview questionnaire to assess socio-demographic characteristics of the studied subjects, tool 2: The Short Form 36 Health Survey (SF-36) that measures the health-related quality of life of patients with various diseases, tool 3: The Emotional Well-Being Scale (EWBS) is a psychological assessment tool developed to evaluate individual emotional experiences and their overall affective well-being, tool 4: Beck Anxiety Inventory (BAI) to measure the severity of anxiety symptoms in adults and adolescents. Data was analyzed at two points: pre- and post-intervention.

. Recommendations: Integrate psychoeducational psychiatric nursing intervention as a standard component of care for patients undergoing Modified Electroconvulsive Therapy (ECT) to enhance cognitive outcomes and emotional well-being.

Inclusion criteria:

• Adults aged 18-65 years,
• diagnosed with major depressive disorder, bipolar disorder, or schizophrenia, - scheduled first time to receive MECT treatment for the first time or had not received MECT for more than six months;
• had no history of substance abuse, organic brain disease, or other severe physical illness;
• and had no contraindications for MECT, such as cardiovascular disease, intracranial hypertension, or epilepsy and able to provide informed consent.

The exclusion criteria were:

• Diagnosed with dementia or severe cognitive impairment, Neurological conditions affecting cognition,
• refusal to participate or inability to complete assessments, dropout, or discontinuation of MECT during the study;
• and occurrence of serious adverse events or complications during the study. .